
SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more
BiotechTV - News
00:00
Ristocell sickle cell differentiation and advantages
John describes Ristocell ex vivo base editing, higher fetal hemoglobin, faster engraftment, and manufacturing benefits.
Play episode from 05:06
Transcript


